Initial Study of Gallbladder Cancer in Chile
Launched by NATIONAL CANCER INSTITUTE (NCI) · Jan 26, 2012
Trial Information
Current as of June 16, 2025
Completed
Keywords
ClinConnect Summary
Gallbladder cancer is a leading cause of cancer death among women in Chile, which has among the highest reported gallbladder cancer incidence and mortality rates in the world. Gallbladder cancer provides a particularly good model for understanding the role of inflammation in carcinogenesis since the major risk factor, gallstones, causes substantial inflammation in the gallbladder. Chile also has a high prevalence of obesity, diabetes, and metabolic syndrome, which are increasingly understood as inflammatory disorders, but the extent to which their carcinogenic effects are mediated through i...
Gender
FEMALE
Eligibility criteria
- -General Case Eligibility Criteria:
- • 18 or older
- • no prior cancer diagnosis (except non-melanoma skin cancer)
- • has gallstones/gallstone disease (including cancer)
- • able to participate alone or have a proxy (a close family member) answer questions about him/her
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Antofagasta, , Chile
Concepcion, , Chile
Santiago, , Chile
Temuco, , Chile
Patients applied
Trial Officials
Jill E. Koshiol, M.D.
Principal Investigator
National Cancer Institute (NCI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials